The Combination of Olaratumab with Doxorubicin and Cisplatinum Regresses a Chemotherapy-Resistant Osteosarcoma in a Patient-Derived Orthotopic Xenograft Mouse Model

Chemotherapy-resistant osteosarcoma is a recalcitrant disease. It is a frequent cause of death to the patients who are usually adolescent or young adults. The goal of the present study was to determine the efficacy of the combination of olaratumab (OLA), doxorubicin (DOX), and cisplatinum (CDDP) on...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Transl Oncol
Main Authors: Higuchi, Takashi, Sugisawa, Norihiko, Miyake, Kentaro, Oshiro, Hiromichi, Yamamoto, Norio, Hayashi, Katsuhiro, Kimura, Hiroaki, Miwa, Shinji, Igarashi, Kentaro, Bouvet, Michael, Singh, Shree Ram, Tsuchiya, Hiroyuki, Hoffman, Robert M.
Formato: Artigo
Idioma:Inglês
Publicado: Neoplasia Press 2019
Assuntos:
Original article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6624322/
https://ncbi.nlm.nih.gov/pubmed/31299622
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.tranon.2019.06.002
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares